Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
- Conditions
- Primary MyelofibrosisMPN-associated Myelofibrosis
- Interventions
- First Posted Date
- 2010-08-10
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 267
- Registration Number
- NCT01178281
- Locations
- 🇵🇱
Centralny Szpital Kliniczny MSWiA, Warsaw, Poland
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇧🇪Universitaire Ziekenhuis Leuven Gathuisberg, Leuven, Belgium
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
- Conditions
- Diffuse Large B-Cell LymphomaMultiple MyelomaNon-Small Cell Lung CancerHepatocellular CarcinomaNeuroendocrine Tumors of Non-Pancreatic OriginHormone Receptor-Positive Breast CancerGlioblastoma Multiforme
- Interventions
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 226
- Registration Number
- NCT01177397
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸UCLA Neuro-Oncology Program, Los Angeles, California, United States
🇺🇸Billings Clinic, Billings, Montana, United States
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma
- Conditions
- Adult T-cell Leukemia-LymphomaPeripheral T-cell Lymphoma
- Interventions
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 13
- Registration Number
- NCT01169298
- Locations
- 🇯🇵
Imamura Bun-in Hospital, Kagoshima, Japan
🇯🇵Nagoya Daini Red Cross Hospital, Nagoya, Japan
🇯🇵Kumamoto University Hospital, Kumamoto, Japan
A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas
- First Posted Date
- 2010-07-15
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 60
- Registration Number
- NCT01163071
- Locations
- 🇺🇸
CTRC @ The Utah Health Science Center @ San Antonio, San Antonio, Texas, United States
🇺🇸Karmanos Cancer Center Institute, Detroit, Michigan, United States
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
- Conditions
- Anemia
- Interventions
- Biological: SotaterceptBiological: Placebo
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Celgene
- Target Recruit Count
- 50
- Registration Number
- NCT01146574
- Locations
- 🇺🇸
North American Research Institute, Azusa, California, United States
🇺🇸Academic Medical Center, Los Angeles, California, United States
🇺🇸Academic Medical Research Institute, Los Angeles, California, United States
Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003
- Conditions
- Myelodysplastic Syndrome
- First Posted Date
- 2010-04-06
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 54
- Registration Number
- NCT01099267
- Locations
- 🇺🇸
Stanford University Cancer Center, Stanford, California, United States
🇺🇸Cancer & Blood Disease Center, Lecanto, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Connect® MM- The Multiple Myeloma Disease Registry
- Conditions
- Multiple Myeloma
- Interventions
- Other: First-line therapyDrug: Second-line Multiple Myeloma treatments
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 3033
- Registration Number
- NCT01081028
- Locations
- 🇺🇸
Medical Arts Associates, Ltd, Moline, Illinois, United States
🇺🇸Hematology Oncology Center, Inc, Elyria, Ohio, United States
🇺🇸US Oncology - Longview Cancer Center, Longview, Texas, United States
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1494
- Registration Number
- NCT01081015
- Locations
- 🇺🇸
Cancer Care Partners, LLC, Mishawaka, Indiana, United States
🇺🇸Illinois Cancer Care, Peoria, Illinois, United States
🇺🇸McFarland Clinic, Ames, Iowa, United States
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Conventional Care Regimen
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 488
- Registration Number
- NCT01074047
- Locations
- 🇧🇪
Grand Hôpital de Charleroi, Charleroi, Hainaut, Belgium
🇦🇹Wilhelminenspital, I Medizinische Abt., Wien, Vienna, Austria
🇵🇱Katedra i Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku, Wroclaw, Dolnoslaskie, Poland
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2013-05-21
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 51
- Registration Number
- NCT01032291
- Locations
- 🇧🇪
ULB Erasme Service de Gastroenterologie, Brussels, Belgium
🇮🇹Azienda Osperdaliero Universitaria Riuniti Umberto I-GM Lancisi-G. Salesi di Ancona Clinica di Oncologia Medica, Ancona, Italy
🇧🇪Grand hôpital de Charleroi, Oncologie, Charleroi, Belgium